Stockreport

Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – Data from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meeting – SOUTH SAN FRANCISCO, Calif., April 15, 2024 BUSIN [Read more]